Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 7/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591671 | 1.00 | GRB2 (0.44) | GRB2OPRK1DPP4FAPDPP8 | |
| SCHEMBL29706282 | 0.96 | DPP4 (0.42) | GRB2OPRK1DPP4FAPDPP8 | |
| SCHEMBL7899895 | 0.94 | GRB2 (0.41) | GRB2OPRK1DPP4FAPDPP8 | |
| SCHEMBL7899891 | 0.94 | GRB2 (0.41) | GRB2OPRK1DPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL7899915 | 0.93 | GRB2 (0.41) | GRB2OPRK1DPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL7899918 | 0.93 | GRB2 (0.41) | GRB2OPRK1DPP4FAPDPP8 | |
| SCHEMBL31696260 | 0.89 | GRB2 (0.44) | GRB2OPRK1OPRM1OPRD1NPFFR2 | |
| SCHEMBL29438447 | 0.88 | DPP4 (0.43) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL29630379 | 0.87 | REN (0.39) | OPRK1OPRM1OPRD1NPFFR2 | |
| SCHEMBL30574235 | 0.86 | DPP4 (0.42) | GRB2DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980667-B2 | Short TAT oligomers for drug delivery | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-05-14 | — | — | US | disclosed |
| US-11807899-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited | 2023-11-07 | — | — | US | disclosed |
| US-20220145378-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980667-B2 | Short TAT oligomers for drug delivery | ACIN1, MYCBP, STAT3 | GRB2 2407/4885OPRK1 957/4885DPP4 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.